Orbitrap Astral MS Literature List 2024

Literature Overview of Orbitrap Astral Mass Spectrometer Applications

Significance of the Topic

The Orbitrap Astral mass analyzer represents a significant advance in high-resolution, high-throughput proteomics. It offers enhanced sensitivity, dynamic range, and acquisition speed, addressing key challenges in modern analytical chemistry. Its ability to deeply characterize complex biological samples—from biofluids to single cells—supports critical applications in biomarker discovery, clinical proteomics, microbiome research, and fundamental studies of post-translational modifications.

Objectives and Study Overview

This curated literature list documents peer-reviewed and preprint research applying the Orbitrap Astral system to diverse fields. The primary goals across studies include:

• Demonstrating deep proteome coverage in biofluids and tissues.
• Applying data-independent acquisition (DIA) and MS/MS-free workflows to uncover novel biological insights.
• Exploring the performance of Astral for single-cell, single-nucleus, and spatial proteomics.
• Evaluating quantitative reproducibility and extending biomarker translation into clinical assays.

Methodology and Used Instrumentation

Key methodological approaches leverage:

• Orbitrap Astral mass analyzer paired with narrow-window DIA and multi-pass acquisition strategies.
• Conjoined rectilinear collision cell and pulsed-extraction ion trap designs for improved ion transmission.
• High-dynamic-range ion detectors and auxiliary DC electrodes to control space charge in the analyzer.
• Integration with digital microfluidic (DMF) chips and Evotip workflows for automated sample processing.
• Ancillary platforms including high‐performance LC systems, microfluidics for single-cell handling, and automated phosphopeptide enrichment rigs.

Main Results and Discussion

Across applications, the Orbitrap Astral delivered:

• Unprecedented depth—over 5,000 proteins identified per single cell and complete one-hour human proteome readouts.
• Rapid, high-throughput quantification of plasma, microbial, and plant proteomes with tight quantitation (CVs <10%).
• Enhanced PTM mapping: extensive phosphoproteome, glycoproteome, and ubiquitylation site occupancy analyses.
• Robust reproducibility in clinical workflows enabling direct translation of DIA-MS candidates into targeted assays.
• Spatial and single-nucleus proteomics revealing tumor microenvironment architecture and developmental phenotypes.

Benefits and Practical Applications

The robust performance of the Orbitrap Astral supports:

• Biomarker discovery pipelines for oncology, neurodegeneration, and immunology.
• Quality control in pharmaceutical development, including vaccine and antibacterials research.
• Functional microbiome analyses via metaproteomics and host-microbe interaction studies.
• High‐throughput screening of PTM dynamics for signaling and stress response investigations.

Future Trends and Opportunities for Use

Emerging directions include:

• Integration with AI-driven data analysis platforms for real-time interpretation.
• Expansion of spatial proteomics with multiplexed imaging and deep visual proteomics workflows.
• Advanced microfluidic and digital sample handling for scalable single-cell and single-nucleus studies.
• Multi-omics integration combining proteome, metabolome, and glycome data for systems-level insights.
• Development of standardized clinical-grade assays using 15N-labeled proteins and targeted methods.

Conclusion

The Orbitrap Astral mass spectrometer has redefined the boundaries of proteomic analysis, offering exceptional depth, speed, and quantitative precision. Its adoption across a wide array of biological and clinical studies underscores its versatility and transformative potential in analytical chemistry. Continued innovation in instrumentation, workflow automation, and computational analysis will further expand its impact on research and diagnostics.